Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-224: Pembrolizumab in advanced HCC
NCT02702414Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- May 2016
- Primary completion
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of pembrolizumab in hepatocellular carcinoma (HCC) (2 cohorts), sponsored by Merck & Co. Primary endpoint: Objective Response Rate at 28 months. Started May 2016; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02702414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02702414.